AFFX Affymetrix, Inc.

Affymetrix, Inc. (Nasdaq:AFFX) today announced that the Company will webcast presentations at 2:30 pm PT on Tuesday, March 28th in Santa Clara, CA as part of the UBS West Coast Life Sciences and Diagnostics Tour. The focus of the program will be an overview of the SNP genotyping market and the Company's products for such applications. The speakers will include: -- Stephen P.A. Fodor, Ph.D., Founder, Chairman and Chief Executive Officer -- Thomas D. Willis, Ph.D., VP DNA Product Marketing and former CSO of ParAllele BioScience -- The program will also include a customer presentation by Timothy J. Triche, M.D., Ph.D., Chief, Department of Pathology, Children's Hospital, Los Angeles; Vice Chair, Department of Pathology, Keck School of Medicine at USC. The webcast will include the Question and Answer session with Company management following the presentations. A webcast of the presentation will be available live and by replay. To access both the live and archived webcast, please go to www.affymetrix.com and click on the "Investors" link. The archived replay will be available 24 hours after the live presentation and will be accessible for 30 days. The webcast will include both audio and slides. For investors who are unable to listen via the webcast, dial-in information for domestic callers for listen only mode will be (866) 500-AFFX, international: (706) 643-2771. About Affymetrix: Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,300 systems have been installed around the world and nearly 3,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,000 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix, Inc.